1309666-78-1

Basic information

• Product Name: Tos-PEG2-t-butyl ester
• Synonyms: Tos-PEG2-t-butyl ester;Tos-PEG1-CH2CH2COOtBu
• CAS NO: 1309666-78-1
• Molecular Formula: C₁₆H₂₄O₆S
• Molecular Weight: 344.42316
• Mol File: 1309666-78-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tos-PEG2-t-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Tos-PEG2-t-butyl ester(1309666-78-1)
• EPA Substance Registry System: Tos-PEG2-t-butyl ester(1309666-78-1)

Safety Data

• Hazardous Substances Data: 1309666-78-1(Hazardous Substances Data)

Usage

Description

Tos-PEG2-t-butyl ester is a PEG linker containing a t-butyl ester and a tosyl group. The hydrophilic PEG spacer increases solubility in aqueous media. The t-butyl protected carboxyl group can be deprotected under acidic conditions. The tosyl group is a very good leaving group for nucleophilic substitution reactions.

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 671802-00-9 3-(2-hydroxyethoxy)propionic acid tert-butyl ester 
• 1663-39-4 tert-Butyl acrylate 
• 104-15-4 toluene-4-sulfonic acid 

Downstream Products

• 1309666-79-2 C₄₄H₅₂O₈ 
• 1260092-46-3 3-(2-aminoethoxy)propionic acid tert-butyl ester 

Relevant articles and documents

Synthesis of Cyclic and Acyclic Nucleoside Phosphonates and Sulfonamides Derived from 6-(Thiophen-2-yl)-7-fluoro-7-deazapurine

Ribonuclosides derived from 6-hetaryl-7-dezapurines are potent cytostatics, but their mechanism of action is unknown. Here we designed and synthesized a series of cyclic and acyclic nucleoside phosphonates, as well as carboxy, cyano, sulfo, and sulfonamide acyclic analogues derived from 6-thiophen-2-yl-7-deazapurine and 7-fluoro-6-thiophen-2-yl-7-deazapurine as ribonucleoside monophosphate mimics. None of these analogues exerted significant cytotoxic and antiviral activity.

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Protein degradation targeting chimera for degrading androgen receptor

The invention relates to a novel difunctional molecule compound based on VHL ligand induction and application of the difunctional molecule compound in synthesis of the compounds and pharmaceutical compositions thereof. The compound is shown as a formula I. The compound can selectively induce AR protein degradation and can be used for treating cancers such as prostatic cancer and breast cancer.